Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical trial

Optimi Health Phase 2 Psilocybin MDD Trial

Analysis based on 15 articles · First reported Sep 10, 2026 · Last updated Sep 23, 2026

Sentiment
5
Attention
2
Articles
15
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The announcement signals Optimi Health's expansion into clinical drug development, potentially strengthening its long-term positioning in the regulated psychedelic medicine sector, though near-term revenue impact is limited as the trial will not begin until 2027. The news may draw investor attention to psychedelic pharmaceutical stocks, but the lack of immediate commercialization and the company's recent stock decline suggest cautious market reaction.

pharmaceuticals biotechnology mental health

Optimi Health announced plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with major depressive disorder. The trial, authorized by Canada — Health Canada, will enroll up to 200 participants across multiple sites in Canada, making it one of the largest clinical studies of naturally derived psilocybin to date. The study will evaluate the safety and efficacy of a single supervised dose of natural psilocybin, with the primary efficacy endpoint being the change in Montgomery-Asberg Depression Rating Scale total score from baseline. Optimi plans to begin the trial in the first half of 2027, with dosing expected to be completed by the end of 2027. The company will supply its own naturally derived psilocybin, manufactured at its GMP-compliant facility in British Columbia, and will retain exclusive ownership of the trial results. Optimi stated it can fund the trial with current cash on hand. Major depressive disorder affects an estimated 332 million people worldwide according to the World Health Organization, and a substantial proportion of patients do not respond adequately to existing antidepressant treatments. Optimi holds a Drug Establishment Licence in Canada and supplies psilocybin through Canada — Health Canada's Special Access Program, with products also prescribed in Australia under its Authorized Prescriber Scheme. None of Optimi's psilocybin drug products have received market authorization from Canada — Health Canada.

90 Optimi Health announced Phase 2 trial
85 Optimi Health completed production batch
70 Canada — Health Canada authorized clinical trial Optimi Health
70 Canada — Health Canada authorized Phase 2 trial Optimi Health
60 Optimi Health supplied Australian clinics Australia
stock
Optimi Health is the central entity initiating the Phase 2 trial, which represents its largest clinical commitment to date and a strategic step toward potential drug registration. The trial could enhance its pipeline and market positioning, though it carries development risks and no near-term revenue.
Importance 100.0 Sentiment 10.0
govactor
Canada — Health Canada authorized the clinical trial, enabling Optimi to proceed with the study. Its regulatory oversight is critical for the trial's legitimacy and future market authorization.
Importance 60.0 Sentiment 0.0
per
As CEO and Co-Founder of Optimi Health, Dane Stevens announced the trial and emphasized its strategic importance. His leadership is tied to the company's clinical development strategy.
Importance 40.0 Sentiment 0.0
cnt
Canada is the location for the trial sites and the regulatory jurisdiction where Optimi operates under Canada — Health Canada's framework. The trial may bolster Canada's position in psychedelic research.
Importance 30.0 Sentiment 0.0
ngo
The World Health Organization is cited for data on major depressive disorder prevalence, providing context for the unmet medical need. It plays no active role in the trial.
Importance 10.0 Sentiment 0.0
cnt
Australia is mentioned as a market where Optimi's products are prescribed under the Authorized Prescriber Scheme, indicating existing international reach. It is not directly involved in the trial.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.